The University of Michigan’s Chad Carr Pediatric Brain Tumor Center has been a key player in developing a new therapy for diffuse midline glioma. Dr. Carl Koschmann, a pediatric oncologist at U-M Health C.S. Mott Children’s Hospital, explains how the drug works and U-M’s role in advancing it. With recent FDA approval, this treatment offers new hope for children and families facing this aggressive brain cancer.
